Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ATHX is in the medium-term down -34% in 5 months.
Description: Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company?s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic
|Shares Outstanding||EPS||-0.3||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||88.4%||Sales Growth - Q/Q||211.06%||P/E||-4.73|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-57.43%||ROE||-121.38%||ROI|
|Current Ratio||2.74||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.74|
|Gross Margin||Operating Margin||-1731.39%||Net Profit Margin||-1401.34%||Dividend Payout Ratio|
|Cash From Financing Activities||8.32 M||Cash From Investing Activities||-60 K||Cash From Operating Activities||1.12 M||Gross Profit|
|Net Profit||-12.48 M||Operating Profit||-6.89 M||Total Assets||40.19 M||Total Current Assets||38.73 M|
|Total Current Liabilities||14.15 M||Total Debt||180 K||Total Liabilities||21.18 M||Total Revenue||730 K|
|High 52 week||2.18||Low 52 week||1.34||Last close||1.41||Last change||-2.76%|
|RSI||44.83||Average true range||0.08||Beta||0.51||Volume||397.95 K|
|Simple moving average 20 days||-5.75%||Simple moving average 50 days||-19.8%||Simple moving average 200 days||-24.02%|
|Performance Week||-9.62%||Performance Month||-26.56%||Performance Quart||-32.21%||Performance Half||-30.2%|
|Performance Year||-24.19%||Performance Year-to-date||-2.08%||Volatility daily||4.79%||Volatility weekly||10.71%|
|Volatility monthly||21.95%||Volatility yearly||76.03%||Relative Volume||350.71%||Average Volume||580.74 K|
|New High||New Low|
2019-03-19 12:03:04 | What Makes Athersys ATHX a New Buy Stock
2019-03-15 17:42:24 | Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT
2019-03-14 19:16:10 | Athersys Inc ATHX Q4 2018 Earnings Conference Call Transcript
2019-03-14 17:04:56 | Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
2019-03-14 14:30:00 | Athersys, Inc. to Host Earnings Call
2019-03-07 08:57:01 | Athersys ATHX Q4 Earnings: What's in Store for the Stock?
2019-02-27 11:04:26 | Is Athersys, Inc.’s NASDAQ:ATHX CEO Paid Enough Relative To Peers?
2019-02-14 08:00:00 | Athersys to Host Year-End 2018 Financial Results Call
2019-01-24 14:20:07 | Athersys' ATHX MultiStem Cell Therapy Succeeds in Study
2019-01-23 09:27:02 | Athersys ATHX Upgraded to Buy: What Does It Mean for the Stock?
2018-11-13 12:29:57 | Are Athersys Inc’s NASDAQ:ATHX Interest Costs Too High?
2018-11-06 21:15:43 | Edited Transcript of ATHX earnings conference call or presentation 6-Nov-18 9:30pm GMT
2018-11-06 16:05:00 | Athersys Reports Third Quarter 2018 Results
2018-10-09 16:00:00 | Athersys to Host Third Quarter Financial Results Call
2018-10-08 10:07:02 | Audentes Therapeutics BOLD Catches Eye: Stock Jumps 7%
2018-10-04 15:18:07 | Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
2018-10-03 11:59:03 | Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
2018-10-02 10:30:00 | Global Stem Cell Market Expected to Reach $270.5 Billion
2018-09-24 06:00:00 | Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
2018-09-20 11:14:50 | Who Are The Major Shareholders Of Athersys Inc NASDAQ:ATHX?
2018-09-14 09:09:01 | The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
2018-09-13 09:14:01 | IPOs and Foreign Investment Propel Biotech: 4 Top Picks
2018-08-20 19:45:47 | Edited Transcript of ATHX earnings conference call or presentation 7-Aug-18 8:30pm GMT
2018-08-16 09:30:01 | Is Athersys ATHX Stock Outpacing Its Medical Peers This Year?
2018-08-07 16:05:00 | Athersys Reports Second Quarter 2018 Results
2018-08-07 14:30:00 | Athersys, Inc. to Host Earnings Call
2018-08-03 06:00:00 | Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
2018-07-12 10:30:00 | Biotechnology Companies Involved in Regenerative Medicine
2018-07-10 16:00:00 | Athersys to Host Second Quarter Financial Results Call
2018-06-29 09:11:01 | 4 Biotech Stocks to Bet on in the Second Half of 2018
2018-06-22 07:26:11 | Athersys Enters Oversold Territory
2018-06-13 07:05:00 | Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities
2018-06-07 08:41:34 | Benzinga Pro's 5 Stocks To Watch Today
2018-06-07 06:00:00 | Athersys Announces Expansion of Collaboration With Healios
2018-06-07 02:01:01 | Athersys Announces Expansion of Collaboration With Healios
2018-06-01 08:42:12 | _Right To Try_ Brings Good News for Biotech Sector: 5 Picks
2018-05-31 11:23:00 | 5 Biotech Stocks to Boost Your Portfolio’s Health This Year
2018-05-31 08:04:12 | 5 Biotech Stocks to Boost Your Portfolio's Health This Year
2018-05-25 10:57:02 | BioMarin's Palynziq Gets FDA Approval for Phenylketonuria
2018-05-23 10:22:02 | INSYS Gets Negative FDA Recommendation for Pain Candidate
2018-05-22 07:24:11 | Moving Average Crossover Alert: Athersys, Inc. ATHX
2018-05-10 19:57:13 | Edited Transcript of ATHX earnings conference call or presentation 10-May-18 8:30pm GMT
2018-05-10 16:03:00 | Athersys Reports First Quarter 2018 Results
2018-05-10 12:11:27 | Athersys Inc NASDAQ:ATHX: Should The Recent Earnings Drop Worry You?